RxDoctor Payments DataLook up a doctor →

Ashok Reddy, MD

Urology · Sterling Heights, MINPI 1720069040

Payments from drug & device makers

$4,890,184in general payments, 2019–2025

Across 231 payments — averaging $21,170 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$4.9M
  • Avyxa Pharma, LLC$5K
  • Ferring Pharmaceuticals Inc.$519
  • Johnson & Johnson$496
  • Medtronic$476
  • Astellas Pharma US Inc$450
  • plus $4K from 37 others

What the payments were for

  • Speaking & faculty fees$2,0000%
  • Travel & lodging$2,1970%
  • Food & beverage$6,6960%
  • Education$1890%
  • Other$4,879,102100%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,890,184 in reported general payments places this provider in the 95th percentile of 400 urology providers in Michigan.

See all urology providers in Michigan

Medicare billing

Part B allowed, 2024
$471,814
Medicare patients
1,189
Services billed
8,194

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MyrbetriqMirabegron105$89,045
GemtesaVibegron31$31,325
Tamsulosin Hcl899$23,031
Mirabegron ErMirabegron34$22,820
Finasteride590$11,621
Terazosin Hcl598$11,545
Trospium Chloride ErTrospium Chloride53$11,292
Alfuzosin Hcl ErAlfuzosin Hcl309$10,121
Tolterodine Tartrate ErTolterodine Tartrate119$9,424
Silodosin92$7,467
Tolterodine Tartrate63$7,020
Potassium Citrate ErPotassium Citrate52$4,466
Trospium Chloride36$3,931
Testosterone Cypionate40$2,200
Dutasteride50$2,190

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncMyrbetriq$450$89,045105 claims
Sumitomo Pharma America, Inc.Gemtesa$152$31,32531 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 400 urology providers in Michigan.

Other urology in Sterling Heights

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →